Overview

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Phase:

Phase 3

Details

Lead Sponsor:

Octapharma